Crestline Management’s Biogen BIIB Stock Holding History

Crestline Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-6,750	Closed	-$1.31M	–	731
2024 Q3	$1.31M	Buy	+6,750	New	+$1.41M	0.07%	237
2022 Q3	–	Sell	-9,595	Closed	-$1.96M	–	215
2022 Q2	$1.96M	Buy	9,595 +3,689	+62%	+$754K	0.26%	86
2022 Q1	$1.24M	Buy	5,906 +193	+3%	+$42K	0.15%	127
2021 Q4	$1.37M	Buy	+5,713	New	+$1.47M	0.1%	132
2021 Q3	–	Sell	-2,852	Closed	-$988K	–	238
2021 Q2	$988K	Buy	+2,852	New	+$864K	0.09%	100
2017 Q4	–	Sell	-11,145	Closed	-$3.49M	–	162
2017 Q3	$3.49M	Buy	11,145 +1,602	+17%	+$474K	0.49%	31
2017 Q2	$2.59M	Buy	+9,543	New	+$2.52M	0.35%	27
2017 Q1	–	Sell	-5,832	Closed	-$1.65M	–	117
2016 Q4	$1.65M	Buy	5,832 +2,262	+63%	+$671K	0.41%	14
2016 Q3	$1.12M	Buy	+3,570	New	+$1.06M	0.14%	81

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Crestline Management's BIIB Position: Q4 2024 in Review

Crestline Management sold out of Biogen (BIIB) in Q4 2024, closing a stake of 6,750 shares — an estimated $1.31M sold.

Crestline Management first reported a position in BIIB in Q3 2016 and held it in 9 quarters. The position peaked at $3.49M in Q3 2017. 875 funds tracked by Wall St. Rank hold BIIB as of Q4 2024.

Crestline Management reported no remaining Biogen position as of Q4 2024 after selling out during the quarter.
Crestline Management sold 6,750 Biogen shares in Q4 2024, an estimated $1.31M.
Crestline Management first reported a position in Biogen in Q3 2016 and held it in 9 quarters.
Crestline Management's Biogen position peaked at $3.49M in Q3 2017.
875 funds tracked by Wall St. Rank held Biogen as of Q4 2024.

Based on Crestline Management's 13F filing for Q4 2024, filed 14 Feb 2025.